Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Boston Scientific Yönetim
Yönetim kriter kontrolleri 3/4
Boston Scientific's CEO'su Mike Mahoney, Oct2011 tarihinde atandı, in görev süresi 11.92 yıldır. in toplam yıllık tazminatı $ 18.72M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.5% maaş ve 92.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler $ 153.54M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.5 yıl ve 8.3 yıldır.
Anahtar bilgiler
Mike Mahoney
İcra Kurulu Başkanı
US$18.7m
Toplam tazminat
| CEO maaş yüzdesi | 7.5% |
| CEO görev süresi | 13yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 8.5yrs |
| Yönetim Kurulu ortalama görev süresi | 8.3yrs |
Son yönetim güncellemeleri
Recent updates
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 18.72M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.04M ).
Tazminat ve Kazançlar: Mike 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Mike Mahoney (59 yo)
13yrs
Görev süresi
US$18,723,735
Tazminat
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 13yrs | US$18.72m | 0.12% $ 156.9m | |
| Executive VP & CFO | 10.8yrs | US$5.83m | 0.015% $ 19.7m | |
| Executive VP & Group President of Cardiology | 14.7yrs | US$5.59m | 0.011% $ 14.6m | |
| Executive VP & President of Peripheral Interventions | 11.8yrs | US$3.78m | 0.0019% $ 2.5m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.3yrs | US$4.27m | 0.0016% $ 2.1m | |
| Executive Vice President of Global Operations | 2.4yrs | Veri yok | 0.0036% $ 4.7m | |
| Senior VP | less than a year | Veri yok | 0.00026% $ 337.2k | |
| Senior VP and Chief Information & Digital Officer | 8.8yrs | Veri yok | Veri yok | |
| Senior VP of Investor Relations | less than a year | Veri yok | 0.0026% $ 3.3m | |
| Senior VP | 3.3yrs | Veri yok | 0.0023% $ 3.0m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.4yrs | Veri yok | Veri yok | |
| Executive Vice President of Human Resources | 11.8yrs | Veri yok | 0.0024% $ 3.1m |
8.5yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: BSX 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 11.9yrs | US$18.72m | 0.12% $ 156.9m | |
| Lead Independent Director | 10.6yrs | US$360.00k | 0.0030% $ 3.9m | |
| Independent Director | 8.5yrs | US$335.00k | 0.0033% $ 4.3m | |
| Independent Director | 8.3yrs | US$320.00k | 0.00020% $ 259.4k | |
| Independent Director | 3.3yrs | US$338.75k | 0.0027% $ 3.5m | |
| Director | less than a year | Veri yok | Veri yok | |
| Director | less than a year | Veri yok | 0.00024% $ 311.3k | |
| Independent Director | 9.5yrs | US$326.25k | 0.0043% $ 5.5m | |
| Independent Director | 15.5yrs | US$340.00k | 0.0036% $ 4.6m | |
| Independent Director | 1.3yrs | US$233.23k | 0.00042% $ 544.7k | |
| Independent Director | 1.3yrs | US$233.23k | 0.00027% $ 350.2k |
8.3yrs
Ortalama Görev Süresi
60.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BSX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).